Phase 2a follow-up period data for RAP-219 in focal onset seizures (FOS) demonstrated sustained seizure reduction, including a 90% median ...

Xenon Pharmaceuticals (NASDAQ:XENE) said it is preparing to submit a new drug application to the U.S. Food and Drug ...

Detailed price information for Rapport Therapeutics Inc (RAPP-Q) from The Globe and Mail including charting and trades.

Epilepsy in children is a chronic neurological condition characterised by two or more unprovoked, recurring seizures resulting from sudden, abnormal electrical activity in the brain, affecting ...

Reported positive topline data from Phase 3 X-TOLE2 study of azetukalner in FOS in March and anticipate NDA submission in Q3 2026Five additional ...

Consideration is set at $31.50 per Catalyst share in cash, implying an equity value above $4.1 billion and a 21% premium to ...

In the quarter, LivaNova delivered 10% organic revenue growth versus the prior year, driven by continued momentum in our cardiopulmonary business and solid neuromodulation performance across all ...

Reported positive topline data from Phase 3 X-TOLE2 study of azetukalner in FOS in March and anticipate NDA submission in Q3 2026Five additional Phase 3 studies of azetukalner continue to enroll in ep ...

NeuroPace (NASDAQ:NPCE) raised its 2026 revenue outlook after reporting first-quarter results that management said reflected continued demand for its RNS System and improving commercial execution ...

NeuroPace, Inc. , a medical device company focused on transforming the lives of people living with drug resistant epilepsy, today announced a major milestone in its clinical evidence program with the ...

Epilepsy is a neurological disorder that causes temporary brain dysfunction. The aftermath of an epileptic seizure varies for each individual and depends on its severity. FITBOOK outlines types of ...

Ripon father Mark Mayatt-Simmons has cycled from Land’s End to John O’Groats, raising more than £2,300 for Leeds-based ...